Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Altimmune, Inc. (NASDAQ: ALT).

Full DD Report for ALT

You must become a subscriber to view this report.


Recent News from (NASDAQ: ALT)

Altimmune's (ALT) CEO Bill Enright on Q1 2018 Results - Earnings Call Transcript
Altimmune, Inc. (ALT) Q1 2018 Results Earnings Conference Call May 16, 2018 05:00 PM ET Executives Bill Enright - CEO Will Brown - Acting CFO Analysts David Sherman - LifeSci Capital Presentation Operator Good day and welcome to the Altimmune First Quarter 2018 Earn...
Source: SeekingAlpha
Date: May, 16 2018 11:47
Altimmune beats by $0.27, beats on revenue
Altimmune (NASDAQ: ALT ): Q1 EPS of -$0.23 beats by $0.27 . Revenue of $2.69M (+796.7% Y/Y) beats by $1.49M . Shares +10% . Press Release More news on: Altimmune, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 15 2018 16:26
Altimmune Announces First Quarter 2018 Financial Results and Provides Corporate Update
Conference call and webcast scheduled for tomorrow, May 16 at 8:30am ET GAITHERSBURG, Md., May 15, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced financial results for the three months ended March 31, 2018. Recent ...
Source: GlobeNewswire
Date: May, 15 2018 16:01
Altimmune to Announce First Quarter 2018 Financial Results on May 16
GAITHERSBURG, Md., May 08, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March 31, 2018 before the market open and host a conference call on Wednesday, M...
Source: GlobeNewswire
Date: May, 08 2018 08:00
FDA accepts Sanofi Pasteur's marketing application for expanded use of flu vaccine
The FDA accepts for review Sanofi Pasteur's ( SNY +0.6% ) supplemental marketing application seeking approval to use the 0.5 mL dose of Fluzone Quadrivalent (influenza vaccine) in children ages six months to 35 months. It is is currently approved for use in kids at least 36 months of age...
Source: SeekingAlpha
Date: April, 25 2018 09:45
Free Research Report as ChemoCentryx's Quarterly Revenues Zoomed More than 1000%; Turned Profitable Y-O-Y
Stock Monitor: Altimmune Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free earnings report on ChemoCentryx, Inc. (NASDAQ: CCXI ). If you want access to this report all you need to do is sign up now by clicking the follow...
Source: ACCESSWIRE IA
Date: April, 19 2018 07:40
Altimmune (ALT) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
The following slide deck was published by Altimmune, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: April, 11 2018 14:35
Altimmune's (ALT) CEO Bill Enright on Q4 2017 Results - Earnings Call Transcript
Altimmune, Inc. (ALT) Q4 2017 Earnings Conference Call March 29, 2018 08:00 ET Executives Paul Arndt - Investor Relations Bill Enright - Chief Executive Officer Elizabeth Czerepak - Chief Financial Officer and Executive Vice President, Corporate Development Sybil Tasker - Chief...
Source: SeekingAlpha
Date: March, 29 2018 10:55
Altimmune reports FY results
Altimmune (NASDAQ: ALT ): FY EPS of -$1.21 Revenue of $10.7M (+234.4% Y/Y) Press Release More news on: Altimmune, Inc., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: March, 28 2018 16:49
Altimmune Announces Financial Results for the Year Ended December 31, 2017 and Provides Corporate Update
Conference call and webcast scheduled for tomorrow, March 29 at 8:30am ET GAITHERSBURG, Md., March 28, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced financial results for the year ended December 31, 2017. Corporat...
Source: GlobeNewswire
Date: March, 28 2018 16:44

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-180.580.5050.580.5021,671,872
2018-05-170.580.5050.580.5021,671,872

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-18127,827212,23660.2287Short
2018-05-17159,324422,12337.7435Short
2018-05-16731,7951,366,56053.5502Short
2018-05-15148,852369,99940.2304Short
2018-05-14364,862603,58660.4490Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALT.


About Altimmune, Inc. (NASDAQ: ALT)

Logo for Altimmune, Inc. (NASDAQ: ALT)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ALT)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 15 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 15 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Amendment to a previously filed 10-K
      Filing Type: 10-K/AFiling Source: edgar
      Filing Date: April, 30 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: April, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 29 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 12 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 09 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 02 2018

       

       


      Daily Technical Chart for (NASDAQ: ALT)

      Daily Technical Chart for (NASDAQ: ALT)


      Stay tuned for daily updates and more on (NASDAQ: ALT)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ALT)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      OTC Report
      @OTCReporter

       

       


      Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of ALT and does not buy, sell, or trade any shares of ALT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/